Improving the duration of immunity for FMD vaccines

Satya Parida

The Pirbright Institute

Oxford, University
Challenges for FMD control in endemic settings through vaccination

Killed inactivated oil adjuvanted vaccines are in use.

Biannual vaccinations (3 PD50 vaccines) are practised to control the disease in endemic settings.

One of the major challenges- short lived immunity (~3 to 4 months max) which allows at least 2 month window for bringing back the disease before 2nd vaccination.

Main aim: To increase the duration of immunity, at least to cover the window between biannual vaccination.
VNT and IFN-γ responses in serotype A and SAT2 vaccinated cattle on 21dpv

Oh et al 2012
www.pirbright.ac.uk
How does the new generation adjuvants help?

- Activate the innate immune system via ligand binding to PRR
- Enhance the anti-viral environment
- Enhance the adaptive response (CMI and humoral)
- Improve memory responses
## Screening of potent adjuvants-I

### Type O antigen (sub-optimal dose) in cattle

<table>
<thead>
<tr>
<th>Groups</th>
<th>No of animals</th>
<th>Details of vaccine</th>
<th>FMD antigen</th>
<th>Adjuvant/ISA 206</th>
<th>Protected/Total</th>
<th>Percent protected</th>
</tr>
</thead>
<tbody>
<tr>
<td>* 1</td>
<td>4*</td>
<td>FMD antigen + Abisco 300 + ISA 206</td>
<td>5 µg</td>
<td>1 mg + 1 ml</td>
<td>3/3</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>4*</td>
<td>FMD antigen + CpG + Emulsigen + ISA 206</td>
<td>5 µg</td>
<td>0.25 mg + 1 ml + 1ml</td>
<td>1/3</td>
<td>33</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>FMD antigen + ISA 70V</td>
<td>5 µg</td>
<td>1 ml</td>
<td>2/4</td>
<td>50</td>
</tr>
<tr>
<td>* 4</td>
<td>4</td>
<td>FMD antigen + ISA 206 + Poly I:C</td>
<td>5 µg</td>
<td>1 ml + 0.4 mg</td>
<td>3/4</td>
<td>75</td>
</tr>
<tr>
<td>* 5</td>
<td>4</td>
<td>FMD antigen + ISA 206 + Imiquimod</td>
<td>5 µg</td>
<td>1 ml + 0.4 mg</td>
<td>3/4</td>
<td>75</td>
</tr>
<tr>
<td>* 6</td>
<td>4</td>
<td>FMD antigen + ISA 206 + MPL-A</td>
<td>5 µg</td>
<td>1 ml + 0.4 mg</td>
<td>3/4</td>
<td>75</td>
</tr>
</tbody>
</table>
### Screening of potent adjuvants- II
Type O antigen (sub-optimal dose): cattle

<table>
<thead>
<tr>
<th>Groups</th>
<th>No of animals</th>
<th>Details of vaccine</th>
<th>FMD antigen</th>
<th>Adjuvant/ISA 206</th>
<th>Protected/Total</th>
<th>Percent protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>4</td>
<td>FMD antigen + Liposome</td>
<td>5 µg</td>
<td>0.2 ml</td>
<td>1/4</td>
<td>25</td>
</tr>
<tr>
<td>8</td>
<td>4</td>
<td>FMD antigen + ISA 206</td>
<td>5 µg</td>
<td>1 ml</td>
<td>2/4</td>
<td>50</td>
</tr>
<tr>
<td>9</td>
<td>4</td>
<td>FMD antigen + ISA 206</td>
<td>10 µg</td>
<td>1 ml</td>
<td>4/4</td>
<td>100</td>
</tr>
<tr>
<td>10</td>
<td>2</td>
<td>PBS alone without FMD antigens</td>
<td>Nil</td>
<td>Nil</td>
<td>0/2</td>
<td>0</td>
</tr>
</tbody>
</table>

*one animal died (non-specific) before the day of challenge (21 dpv). Animals were vaccinated intramuscularly on one occasion and challenged by the intradermolingual route with log$10^4$ CCID$_{50}$ dose of FMDV O/IND/R2/75, 3 weeks later.
Final screening of potent adjuvants using Type A antigen (sub-optimal dose) in cattle

<table>
<thead>
<tr>
<th>Group</th>
<th>No of animals</th>
<th>Vaccine details</th>
<th>A22 FMD antigen</th>
<th>Protected / Total</th>
<th>Percentage of protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>None</td>
<td>None</td>
<td>0/2</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>A22 FMD antigen+ISA-206</td>
<td>2 μg</td>
<td>0/5</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>A22 FMD antigen+ISA206 +AbiSCO®300</td>
<td>2 μg</td>
<td>5/5</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
<td>A22 FMD antigen+ISA-206 +Poly(I:C)</td>
<td>2 μg</td>
<td>5/5</td>
<td>100</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>A22 FMD antigen+ISA-206 +MPLA</td>
<td>2 μg</td>
<td>4/5</td>
<td>80</td>
</tr>
<tr>
<td>6</td>
<td>5</td>
<td>A22 FMD antigen+ISA-206 +R848</td>
<td>2 μg</td>
<td>2/5</td>
<td>40</td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>A22 FMD antigen+ISA-206 +MPLA+R848</td>
<td>2 μg</td>
<td>1/5</td>
<td>20</td>
</tr>
</tbody>
</table>
Serotype A Vaccine Trial Design

A22 Iraq+ ISA-206 control

A22 Iraq+ ISA-206 + poly (I:C) adjuvant

A22 Iraq+ ISA-206 + AbISCO adjuvant

A22 Iraq+ ISA-206 + R848 adjuvant

A22 Iraq+ ISA-206 + MPLA adjuvant

A22 Iraq+ ISA-206 + R848+ MPLA adjuvant

Non-Vaccinates control

A22 Iraq Vaccination (sub-optimal dose)

A22 Iraq Challenge

Sampling
Daily Rectal Temp Swabs
Clotted blood
Heparinized blood

Cull
All calves had viraemia and sub-clinical infection

Genome copy in nasal secret

Abs in peripheral serum to NSP

Adjuvant Included in ISA-206+A22 vaccine
FACS analysis- IFN-γ from CD4+ and CD8+ cells
Poly (I:C) and AbISCO had significantly increased neutralizing antibodies on 28dpv compared to the ISA-206 control group.

Adjuvant Included in ISA-206+A22 vaccine
Summary-1

- Achieved an increased potency as indicated by lack of clinical symptoms in Poly I:C and AbISCO groups (although not able to prevent sub-clinical infection)

- Significantly elevated neutralizing antibodies in Abisco and Poly I:C group cattle

- Some indication of IFN-g upregulation by CD4\(^+\) and CD8\(^+\) cells
Longer duration of immunity study

ISA 206 + Poly I:C 11 cattle

ISA 206 11 cattle

Type O antigen full dose - 10 microgram

Vaccinated cattle were monitored for 225 days (7.5 months) at Indian Immunologicaals

Serum, PBMC and antigen specific stimulated whole blood plasma were transported to Pirbright for analysis
Virus neutralisation titres

- Titres significantly higher in cattle when vaccinated with poly I:C (blue) compared with conventional adjuvant (red)
Whole blood Interferon-γ

- Significantly higher levels in cattle when vaccinated with poly I:C (blue) compared with conventional adjuvant (red)
IFN-γ production - flow cytometry on 120 dpv

% of CD4 or CD8 cells from the total live population showing antigen specific IFNγ expression
Summary-2

- Significantly higher VN titre in cattle vaccinated with poly I:C compared with conventional adjuvant
- By 4th month many of the conventional vaccinated animals lost the protective level of antibody titre
- IFNγ levels significantly higher in cattle when vaccinated with poly I:C when compared with conventional adjuvant
- Indication of IFN-gamma upregulation by CD4^+ and CD8^+ cells were observed in Poly I:C group in FACS analysis.
- Duration of immunity can be enhanced up to 6 months post-vaccination that covers the window of susceptibility before 2^{nd} vaccination
Acknowledgements

Katie Lloyds-Jones
Mana Mahapatra
Krupali Parekh
Katy Moffat
Becky Herbert
Aravindh Babu

Simon Gubbins
David Paton
Geraldine Taylor

Indian Immunological
Dr V.A Srinivasan
Dr S B NagendraKumar
Dr M Madhanmohan
Dr R Lingala

Funding:
BBSRC
DFID, UK